About Us

Pidnarulex(CX-5461)

• Phase 1b clinical data selected for presentation at the 2024 ESMO Annual Meeting.

Silmitasertib(CX-4945)

• Selected for clinical trial medication by the renowned Beat Childhood Cancer Research Consortium

Silmitasertib(CX-4945)

• Granted Rare Pediatric Disease designation (RPDD) by the U.S. FDA for use in neuroblastoma.

Silmitasertib(CX-4945)

• Granted Orphan Drug Designation (ODD) by the U.S. FDA for use in neuroblastoma.

Pidnarulex(CX-5461)

• Selected for the five-year cancer-fighting program NCI-NExT, sponsored by the National Cancer Institute of the United States.

Silmitasertib(CX-4945)

• Phase I clinical data for Basal Cell Carcinoma selected for presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

Pidnarulex(CX-5461)

• Winner of Pfizer/PCF Global Challenge Awards

Pidnarulex(CX-5461)

• Combination with Talazoparib to treat prostate cancer

Silmitasertib(CX-4945)

• Named as potential Covid-19 therapy by the University of California San Francisco, Quantitative Biosciences Institute (QBI-UCSF) / The Institute for Antiviral Research, Utah State University ( IAR-USU) respectively and published in the scientific journal Cell

Silmitasertib(CX-4945)

• Grant awarded by US NIH-CTEP Program and collaborated with PBTC to study the drug in the treatment of Medulloblastoma (MB)

Pidnarulex(CX-5461)

• SU2C Breast Cancer Dream Team Drug Winner

Silmitasertib(CX-4945)

• Granted Orphan Drug Designation by the US FDA in Cholangiocarcioma